Flash FinanceUS
Market open S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Cardiff Oncology, Inc. (CRDF)

Cardiff Oncology settles Nerviano suit and amends onvansertib license agreement

Mixed Impact 3 of 5 legal/regulatory Written later

Cardiff Oncology and Nerviano Medical Sciences agreed on September 14, 2026 to settle their pending litigation, with both parties dismissing the case with prejudice and exchanging mutual releases, and no monetary payment made between them. The companies also amended the 2017 license agreement for onvansertib, changing exclusivity, royalty, milestone, governance and assignment terms, which matters to shareholders because it reshapes the economics and conditions of the company's lead asset.

Key points

  • Settlement and Amendment dated September 14, 2026; the Amendment takes full effect when the case is dismissed with prejudice.
  • No monetary payment was made by either party to resolve the litigation, and neither party admitted liability.
  • Amendment adds an additional license fee on annual net sales of products practicing a valid Company patent claim, in lieu of the existing royalty.
  • If Cardiff assigns the license, including by merger or change of control, before Phase III data readout, it would owe Nerviano a percentage of transaction proceeds based on Phase III dosing timing.

The filing

CompanyCardiff Oncology, Inc. (CRDF)
Form8-K, current report
Filed with the SECSep 14, 2026, 9:28 AM ET
Accession number0001493152-26-042506

Items reported: 1.01 Material Definitive Agreement7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:36 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on September 14, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.